Home » Newsletters » BioWorld Science

BioWorld Science

March 10, 1998

View Archived Issues

Peptech: Annual Report 1997

Clinical syndromes associated with zafirlukast therapy in patients with asthma

Company Profile: Dura

Onyx: Q4 and year-end 1997 highlights

Cambridge NeuroScience: Q4 and year-end 1997 highlights

Organizational changes underway at AHP

First approval for RPR's new combination patch

CLEAR indications of Abelcet efficacy

Sibia Neurosciences: Q4 and year-end 1997 highlights

PLC Systems: Q4 and year-end 1997 highlights

New ACAT-inhibitory malondiamido derivatives from Sanwa

Dual angiotensin II/alpha1-adrenoceptor blockers described by Kyorin

Testosterone 5alpha-reductase inhibitors disclosed by Sumitomo Metal

Janssen describes a new cell migration inhibitor

New antimigraine candidates described by Allelix

Peptech reports novel antiinfective peptides

Nitrullin evaluated in phase II for melanoma

New antimitotic agent described by Czech investigators

Degussa-Huls merger underway

Chiroscience creates Rapigene subsidiary

Boston Life Sciences licenses BCLx-gamma gene from Harvard

PowderJect and Glaxo Wellcome enter DNA vaccine collaboration

Troponin I closer to entering clinical trials

Advanced Magnetics in-licenses contrast agent from Andaris

UT-15 will move to phase III for pulmonary hypertension

First Rx for HIT type II approved in U.S.

Cipro HC approved for otitis

New formulation of methioninase looks promising for clinical testing

PGG-glucan displays potent protective effects in guinea pig model

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...